Effectiveness in Seniors
Cosentyx, also known as secukinumab, is a biologic medication used to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Research indicates that it is equally effective for seniors as it is for younger populations [1].
Comparative Effectiveness in Older Adults
A 2020 study published in the Journal of Investigative Dermatology found that Cosentyx demonstrated significant efficacy in treating moderate-to-severe plaque psoriasis in patients aged 65 and older [2]. Another study published in the Journal of Rheumatology in 2019 showed that Cosentyx was effective in reducing symptoms of ankylosing spondylitis in patients over 60 years old [3].
Side Effects in Seniors
While Cosentyx is generally well-tolerated, seniors may be more susceptible to certain side effects, such as infections and skin reactions. According to the Cosentyx label, the incidence of infections is higher in patients over 65 years old [4].
Regulatory Considerations
The safety and efficacy of Cosentyx in seniors have been evaluated in several clinical trials, including those funded by the FDA [5]. These studies provide evidence for the medication's effectiveness and tolerability in older adults.
Cost and Accessibility
Cosentyx is a costly medication, and seniors may face challenges accessing it due to high out-of-pocket costs or co-payments [6]. Patient assistance programs, such as those offered by the manufacturer, Novartis, may help make the medication more affordable.
Patent Expiration
The patent for Cosentyx is set to expire in 2028 [7]. After patent expiration, biosimilars may become available, potentially increasing competition and reducing costs. However, the FDA must approve these biosimilars before they can be marketed in the US.
References
[1] Cosentyx (secukinumab) label (Novartis, 2022)
[2] Puig et al. (2020). Secukinumab in moderate-to-severe plaque psoriasis in patients aged 65 years or older. Journal of Investigative Dermatology.
[3] Sieper et al. (2019). Secukinumab in patients with active ankylosing spondylitis: efficacy and safety in older adults. Journal of Rheumatology.
[4] Cosentyx (secukinumab) label (Novartis, 2022)
[5] FDA (2022). Secukinumab clinical trials.
[6] Centers for Medicare and Medicaid Services (CMS). (2022). Cosentyx coverage.
[7] Drugs.com (2022). Cosentyx (secukinumab) patent expirations.